Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
Bristol-Myers Squibb Pharma Company
Liqi He
Paul Joseph Gilligan
Argyrios Georgios Arvanitis
Robert John Chorvat
The Du Pont Merck Pharmaceutical Company
Du Pont Pharmaceuticals Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Pharma Company, Liqi He, Paul Joseph Gilligan, Argyrios Georgios Arvanitis, Robert John Chorvat, The Du Pont Merck Pharmaceutical Company, Du Pont Pharmaceuticals CompanyfiledCriticalBristol-Myers Squibb Pharma Company
Priority claimed from US08/899,242external-prioritypatent/US6124289A/en
Priority claimed from CA002259583Aexternal-prioritypatent/CA2259583C/en
Publication of CA2532925A1publicationCriticalpatent/CA2532925A1/en
Application grantedgrantedCritical
Publication of CA2532925CpublicationCriticalpatent/CA2532925C/en
Corticotropin releasing factor (CRF) antagonists of formula I or II: (see formula I) (see formula II) wherein A is CR, and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.
CA002532925A1996-07-241997-07-23Azolo triazines and pyrimidines
Expired - LifetimeCA2532925C
(en)
4-(2-BUTYLAMINO-2, 7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-yl) PYRAZOLO-[1,5-a]-1,3,5-TRIAZINE, ITS ENANTIOMERS AND PHARMACEUTICALLY ACCEPTABLE SALTS AS CORTICOTROPIN RELEASING FACTOR RECEPTOR LIGANDS
Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders